INS and metabolic dysfunction-associated steatohepatitis: The agonistic activity on FXR was beyond the pharmacological role of UDCA (Liu et al., 2014), while obeticholic acid acting as a FXR agonist could significantly improve hepatic steatosis and increase insulin sensitivity in NASH patients (Neuschwander-Tetri et al., 2015).